Public pharmaceutical expenditure (pharmacies) in Spain

25 April 2016
spain-big-2

Data from the Spanish Ministry of Health, Social Services and Equality shows that in January, public pharmaceutical expenditure at pharmacies experienced a growth of 1.67%, compared to the registered accumulated figure of January 2015.

This variation in expenditure is due to a rise in the number of prescriptions (+0.95%) and an increase in the average price of prescriptions (+0.72%). The accumulated expenditure to 12-months in January was 3.21 million euros ($3.6 million) lower than the recorded high in May 2010 (a 25.3% decline), according to a posting on trade group Farmaindustria’s website.

In annual terms, pharmaceutical expenditure fell -1.03% in January in comparison to January 2015. The drop was primarily brought about by the significant reduction in the demand side for prescriptions (-4.6%) and the main reason behind this is that January 2016 has one working day less than January 2015; this has an immediate impact on the turnover of prescriptions. Similarly, it is expected to see a circumstantial increase on the demand side in February in comparison to February 2015, produced by the same fact, however this time it will be contrary to January as February 2016 was a leap-year and so it had one extra working day than in the previous year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical